This amendment introduces an exclusive GMP suite at the AGC Biologics Cell and Gene Center of Excellence in Milan, dedicated to the manufacturing of Genenta’s cell therapy product, ...

This amendment introduces an exclusive GMP suite at the AGC Biologics Cell and Gene Center of Excellence ... at INNOVIT - Italian Innovation and Culture Hub in San Francisco.

This amendment introduces an exclusive GMP suite at the AGC Biologics Cell and Gene Center of Excellence in Milan, dedicated to the manufacturing of Genenta's cell therapy product, ensuring ...

This amendment introduces an exclusive GMP suite at the AGC Biologics Cell and Gene Center of Excellence ... at INNOVIT – Italian Innovation and Culture Hub in San Francisco.

MILAN and NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that it has ...

JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth and improved margins. Although the newsthat WuXi Bio ...

Wuxi Biologics (WXXWY) plans to sell its Irish vaccine facility to Merck (MRK) for around $500M ahead of potential U.S. legislation that would limit business for Chinese biotech companies ...

Under the terms of the agreement, Candid will have exclusive global rights to a preclinical trispecific T-cell Engager discovered at WuXi Biologics' proprietary universal ... expedite the process by 6 ...

Dr. Chris Chen, CEO of WuXi Biologics, commented, “We’re glad to enable Candid to advance the progress of T-cell engagers through WuXiBody TM. This collaboration not only showcases the platform’s ...

Candid Therapeutics is continuing its mission to flesh out a pipeline of T-cell engagers in record time, signing a $925 million biobucks deal with WuXi Biologics for a preclinical candidate.